The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Opdivo (nivolumab) on May 20, 2021. This significant regulatory action, identified as BLA 125554 S-92, was based on new efficacy data submitted by the sponsor, Bristol Myers Squibb, indicating an expansion of the drug's approved uses.
Background
Nivolumab is a key pharmaceutical agent known by its brand name Opdivo. Developed by Bristol Myers Squibb, nivolumab is also a component in other therapeutic combinations, such as nivolumab and relatlimab-rmbw (Opdualag) and nivolumab and hyaluronidase-nvhy (Opdivo Qvantig). A supplemental application, like the one approved, typically seeks to add new information to an existing approved drug application, often reflecting new clinical evidence of the drug's effectiveness for an expanded use or patient population. This particular supplemental approval was specifically categorized under "Efficacy."
What this means
The FDA's supplemental approval for Opdivo (nivolumab) based on efficacy data indicates that the agency has reviewed and accepted additional clinical evidence demonstrating the drug's effectiveness for an expanded application. While the specific new indication or patient population is not detailed in this record, such approvals are vital for broadening patient access to effective treatments. This process allows pharmaceutical companies like Bristol Myers Squibb to update existing drug labels with new data, ensuring that healthcare providers have the most current information regarding a drug's approved uses and benefits. The "major" importance classification of this event underscores its potential impact on patient care and treatment strategies involving nivolumab, suggesting a significant update to its therapeutic profile.
Source
The information regarding this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA). Details for supplemental application BLA 125554 S-92, including its approval date of May 20, 2021, are publicly available on accessdata.fda.gov.